To access the live webcast of bluebird bio’s fireside chat, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the conference.
About bluebird bio, Inc.
With its lentiviral-based gene
therapy and gene editing capabilities, bluebird bio has built an
integrated product platform with broad potential application to severe
genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical
programs include Lenti-D™, currently in a Phase 2/3 study, called the
Starbeam Study, for the treatment of childhood cerebral
adrenoleukodystrophy, and LentiGlobin®, currently in three clinical
studies: a global Phase 1/2 study, called the Northstar Study, for the
treatment of beta-thalassemia major; a single-center Phase 1/2 study in
bluebird bio has operations in
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
bluebird bio’s existing product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk that
previously conducted studies involving similar product candidates will
not be repeated or observed in ongoing or future studies involving
current product candidates, the risk of cessation or delay of any of the
ongoing or planned clinical studies and/or our development of our
product candidates, the risk of a delay in the enrollment of patients in
our clinical studies, the risk that our collaboration with
View source version on businesswire.com: http://www.businesswire.com/news/home/20150924006340/en/
Source: bluebird bio, Inc.
Investor Relations
bluebird bio, Inc.
Manisha Pai,
617-245-2107
mpai@bluebirdbio.com
or
Media
Contact
Pure Communications, Inc.
Dan Budwick, 973-271-6085